Zevra Therapeutics, Inc.

Healthcare

NASDAQ:ZVRA · NASDAQ Global Select

Market Cap $762.58M Beta 0.89 P/E (TTM) 6.1

$12.90 +2.44%

+$0.31 today

52W Low $7.16High $14.27

Vol 1.72M · Avg 1.43M

EPS (TTM) $2.13Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+43.33%

Period High

$13.66

Period Low

$7.23

Latest

$12.90

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B

Ventyx Biosciences, Inc.

VTYX

$1.00B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$992.27M

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

$801.79M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

$604.46M

Prothena Corporation plc

NASDAQ:PRTA

$459.66M

REGENXBIO Inc.

NASDAQ:RGNX

$417.05M

Niagen Bioscience Inc

NASDAQ:NAGE

$278.36M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

$274.96M

Gossamer Bio, Inc.

GOSS

$39.38M

What is the latest ZVRA filing?

The latest filing shown is 8-K dated Jun 5, 2026.

How many recent filings does ZVRA have?

Intrinsic Alpha currently shows 20 recent filings for ZVRA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.